High‐ and Low‐Dose Oral Delayed‐Release Mesalamine in Children With Mild‐to‐Moderately Active Ulcerative Colitis
Harland S. Winter(Massachusetts General Hospital), Preston Dunnmon(United States Food and Drug Administration), Barbara Iwańczak(Wroclaw Medical University), Jarosław Kierkuś(Children's Memorial Health Institute), B. O. Osuntokun(Cook Children's Medical Center), Sanja Kolaček(University of Zagreb), Piotr Krzeski(Postgraduate School of Molecular Medicine), Bruce Yacyshyn(University of Alberta), M Kaczmarski(Medical University of Białystok), Melvin B. Heyman(University of California, San Francisco), J. Antonio Quiros(Medical University of South Carolina), Manoj Shah(Loma Linda University Children's Hospital), Eduardo Ibarguen‐Secchia(Methodist Children’s Hospital)
Cited by 25
Related Papers
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
|Gastroenterology|2006|872
Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report
|PEDIATRICS|2010|870
Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry
|The Journal of Pediatrics|2005|571
Management of Pediatric Ulcerative Colitis
|Journal of Pediatric Gastroenterology and Nutrition|2012|377